Coastline Trust Co Has $4.08 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

Coastline Trust Co lowered its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 6.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 37,389 shares of the company’s stock after selling 2,577 shares during the quarter. Coastline Trust Co’s holdings in Merck & Co., Inc. were worth $4,076,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRK. Ruedi Wealth Management Inc. lifted its position in shares of Merck & Co., Inc. by 180.2% during the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. AlphaMark Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $34,000. Valued Wealth Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $42,000. TFO Wealth Partners LLC lifted its position in shares of Merck & Co., Inc. by 108.1% during the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock worth $48,000 after purchasing an additional 241 shares during the last quarter. Finally, Ameliora Wealth Management Ltd. acquired a new position in shares of Merck & Co., Inc. during the 3rd quarter worth about $50,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRK. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. StockNews.com raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target on the stock. in a research note on Monday, March 11th. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, March 27th. Finally, Barclays boosted their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.71.

Check Out Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Down 0.5 %

MRK stock traded down $0.64 during trading hours on Tuesday, reaching $130.35. 6,550,741 shares of the stock were exchanged, compared to its average volume of 8,717,681. The firm’s 50-day moving average is $125.24 and its 200-day moving average is $113.04. The company has a market cap of $330.13 billion, a price-to-earnings ratio of 935.21, a PEG ratio of 0.52 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The company had revenue of $14.63 billion during the quarter, compared to analysts’ expectations of $14.49 billion. During the same quarter last year, the company earned $1.62 EPS. Merck & Co., Inc.’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities research analysts expect that Merck & Co., Inc. will post 8.59 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 2.36%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 2,200.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.